Bond.az White LogoBond.az Black Logo

PJM board letter positive for power producers

Melius Research sees PJM board letter as positive for independent power producers. Vistra shares up 16%, regulatory changes and market outlook.

Mia Lopez
ByMia Lopez- Senior Editor
|
0

Melius Research views the May 19 PJM Board of Managers letter as a structural positive for independent power producers, according to analyst commentary following discussions with firms including Vistra Corp., Talen Energy Corp., and Constellation Energy Corp.

The letter accelerates the centralized Reliability Backstop Procurement auction to September 2026 from early 2027. Executive teams broadly characterized the letter as very positive, removing approximately six months of regulatory limbo. Analysts remain bullish on Vistra, with revenue climbing 7.4% over the last twelve months.

PJM's Board merged the RBP and Connect and Manage proceedings into a single CIFP process, ending dual-track confusion. Melius says bundling C&M into the Backstop CIFP forces FERC to evaluate the construct as part of a single package, raising the probability of acceptance.

PJM has written to each state governor requesting frameworks to allocate backstop costs to new large load customers. If states do not act, costs default to residential consumers, creating political risk.

The 2027/2028 BRA closed with a shortfall of approximately 6,500 MW. PJM's RBP proposal targeted approximately 14.9 GW of new capacity through 2029. Bond.az data shows Vistra trading near its Fair Value, with analysts setting price targets as high as $320.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...